Early End to Medicare Subsidies
The Centers for Medicare and Medicaid Services (CMS) have announced that the Biden-era Medicare Part D drug subsidies will end after 2026. Medicare Part D coverage is optional and provides prescription drug coverage for Medicare beneficiaries, whether via standalone insurance or in combination with a Medicare Advantage plan. The Biden-era program implemented a $2,000 cap on participants' annual out-of-pocket spending on prescription drugs. The program was originally created in 2024 and, according to CMS, could last for at least three years.
We asked two professors and authors of ALM's Tax Facts with opposing political viewpoints to share their opinions about the Trump administration's decision to end the Biden-era Medicare drug subsidies early.
Below is a summary of the debate that ensued between the two professors.
Their Votes:
Their Reasons:
Byrnes: It absolutely makes sense to end these ineffective Biden-era Medicare drug subsidies early. The Biden administration gave away billions of dollars to the biggest insurance companies out there--all at the expense of the American people. Ending the subsidies early allows the government to focus on price-reducing strategies that actually work in the prescription drug arena--such as working with manufacturers to negotiate lower, more fair, drug pricing.
Bloink: Ending these valuable Medicare subsidies early flies in the face of the reality that Americans are currently faced with when it comes to affordability--and seems to further demonstrate that the Trump administration is out of touch with the financial strain currently impacting millions of Americans. Ending these subsidies early shows that the GOP is not prioritizing the affordability of healthcare in America—especially as this move comes on the tailwinds of the GOP decision to eliminate Affordable Care Act subsidies that allowed millions of Americans to afford health coverage.
_________________________________________
Byrnes: The fact is the current administration has already stabilized the market when it comes to drug prices. These subsidies are not necessary—and have never been effective. Negotiating with insurance companies directly is a much more effective strategy for reducing overall prescription drug costs for Medicare beneficiaries.
Bloink: Cutting the Medicare Part D drug subsidies effectively increases the cost of healthcare for millions of Americans who rely upon Medicare prescription drug coverage. There's no other way to spin this move. The savings to the government by ending these subsidies will be minimal. By some accounts, this program costs the federal government $5 billion per year—while the war with Iran is costing upwards of $100 billion. We can't pretend that it will tip the scales when it comes to reigning in excessive spending under this second Trump administration. The cost to Medicare beneficiaries, on the other hand, will be significant.
_________________________________________
Byrnes: These Biden-era subsidies only serve to perpetuate fraud, waste and abuse in the Medicare arena. Studies show that any premium cost increases will be minimal--and many beneficiaries will actually see a cost reduction. What we're doing is ending a bailout that simply did not work in favor of more effective strategies to keep drug prices down for Americans.
Bloink: The subsidy program has been proven to be effective when it comes to lowering the amount that Medicare beneficiaries are required to pay for their prescription drugs. This decision will undoubtedly result in those Americans paying more for their prescription drug coverage. This will further increase financial pressure for millions of Americans who are already struggling under the weight of sky-high energy and food prices.